ABUS Annual CFO
-$85.94 M
-$50.58 M-143.06%
31 December 2023
Summary:
As of January 23, 2025, ABUS annual cash flow from operations is -$85.94 million, with the most recent change of -$50.58 million (-143.06%) on December 31, 2023. During the last 3 years, it has fallen by -$34.49 million (-67.06%). ABUS annual CFO is now -361.14% below its all-time high of $32.91 million, reached on December 31, 2012.ABUS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABUS Quarterly CFO
-$20.74 M
-$6.23 M-42.97%
30 September 2024
Summary:
As of January 23, 2025, ABUS quarterly cash flow from operations is -$20.74 million, with the most recent change of -$6.23 million (-42.97%) on September 30, 2024. Over the past year, it has dropped by -$1.44 million (-7.47%). ABUS quarterly CFO is now -151.38% below its all-time high of $40.36 million, reached on December 31, 2012.ABUS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABUS TTM CFO
-$71.83 M
+$1.05 M+1.44%
30 September 2024
Summary:
As of January 23, 2025, ABUS TTM cash flow from operations is -$71.83 million, with the most recent change of +$1.05 million (+1.44%) on September 30, 2024. Over the past year, it has increased by +$6.10 million (+7.83%). ABUS TTM CFO is now -309.23% below its all-time high of $34.33 million, reached on March 31, 2013.ABUS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABUS Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -143.1% | -7.5% | +7.8% |
| 3 y3 years | -67.1% | -22.1% | -103.2% |
| 5 y5 years | -26.6% | -22.1% | -103.2% |
ABUS Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -143.1% | at low | -200.6% | +24.1% | -147.4% | +16.4% |
| 5 y | 5-year | -143.1% | at low | -200.6% | +24.1% | -147.4% | +16.4% |
| alltime | all time | -361.1% | at low | -151.4% | +24.1% | -309.2% | +16.4% |
Arbutus Biopharma Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$20.74 M(+43.0%) | -$71.83 M(-1.4%) |
| June 2024 | - | -$14.50 M(-24.8%) | -$72.88 M(-6.5%) |
| Mar 2024 | - | -$19.30 M(+11.6%) | -$77.93 M(-9.3%) |
| Dec 2023 | -$85.94 M(+143.1%) | -$17.29 M(-20.6%) | -$85.94 M(+0.4%) |
| Sept 2023 | - | -$21.78 M(+11.4%) | -$85.63 M(+3.7%) |
| June 2023 | - | -$19.56 M(-28.4%) | -$82.54 M(-0.9%) |
| Mar 2023 | - | -$27.30 M(+60.7%) | -$83.28 M(+135.5%) |
| Dec 2022 | -$35.36 M(-47.6%) | -$16.99 M(-9.1%) | -$35.36 M(-6.9%) |
| Sept 2022 | - | -$18.69 M(-7.9%) | -$37.97 M(+7.5%) |
| June 2022 | - | -$20.29 M(-198.4%) | -$35.32 M(+21.6%) |
| Mar 2022 | - | $20.62 M(-205.2%) | -$29.03 M(-57.0%) |
| Dec 2021 | -$67.53 M(+31.3%) | -$19.61 M(+22.3%) | -$67.53 M(+7.3%) |
| Sept 2021 | - | -$16.04 M(+14.5%) | -$62.94 M(+6.5%) |
| June 2021 | - | -$14.01 M(-21.7%) | -$59.08 M(+9.7%) |
| Mar 2021 | - | -$17.88 M(+19.1%) | -$53.87 M(+4.7%) |
| Dec 2020 | -$51.44 M(-27.6%) | -$15.01 M(+23.3%) | -$51.44 M(+3.3%) |
| Sept 2020 | - | -$12.17 M(+38.3%) | -$49.78 M(-18.5%) |
| June 2020 | - | -$8.80 M(-43.0%) | -$61.08 M(-12.6%) |
| Mar 2020 | - | -$15.45 M(+15.7%) | -$69.88 M(-1.6%) |
| Dec 2019 | -$71.01 M(+4.6%) | -$13.35 M(-43.1%) | -$71.01 M(-5.0%) |
| Sept 2019 | - | -$23.47 M(+33.3%) | -$74.73 M(+15.9%) |
| June 2019 | - | -$17.61 M(+6.2%) | -$64.46 M(-0.0%) |
| Mar 2019 | - | -$16.58 M(-2.9%) | -$64.48 M(-5.0%) |
| Dec 2018 | -$67.87 M(+39.5%) | -$17.07 M(+29.3%) | -$67.87 M(+11.0%) |
| Sept 2018 | - | -$13.20 M(-25.1%) | -$61.13 M(-3.9%) |
| June 2018 | - | -$17.62 M(-11.7%) | -$63.61 M(+24.6%) |
| Mar 2018 | - | -$19.97 M(+93.1%) | -$51.07 M(+5.0%) |
| Dec 2017 | -$48.64 M(-16.0%) | -$10.34 M(-34.0%) | -$48.64 M(-8.4%) |
| Sept 2017 | - | -$15.68 M(+208.6%) | -$53.12 M(+1.9%) |
| June 2017 | - | -$5.08 M(-71.0%) | -$52.15 M(-18.4%) |
| Mar 2017 | - | -$17.54 M(+18.3%) | -$63.87 M(+10.3%) |
| Dec 2016 | -$57.88 M(+2.7%) | -$14.82 M(+0.7%) | -$57.88 M(-5.5%) |
| Sept 2016 | - | -$14.71 M(-12.5%) | -$61.28 M(+24.8%) |
| June 2016 | - | -$16.80 M(+45.5%) | -$49.09 M(-2.0%) |
| Mar 2016 | - | -$11.55 M(-36.6%) | -$50.09 M(-11.2%) |
| Dec 2015 | -$56.38 M | -$18.21 M(+620.8%) | -$56.38 M(+25.3%) |
| Sept 2015 | - | -$2.53 M(-85.8%) | -$45.01 M(-8.5%) |
| June 2015 | - | -$17.80 M(-0.3%) | -$49.21 M(+24.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | -$17.84 M(+160.6%) | -$39.42 M(+217.4%) |
| Dec 2014 | -$12.42 M(+84.4%) | -$6.85 M(+1.9%) | -$12.42 M(+312.9%) |
| Sept 2014 | - | -$6.72 M(-16.1%) | -$3.01 M(-7261.9%) |
| June 2014 | - | -$8.01 M(-187.5%) | $42.00 K(-99.2%) |
| Mar 2014 | - | $9.15 M(+256.6%) | $5.26 M(-178.0%) |
| Dec 2013 | -$6.74 M(-120.5%) | $2.57 M(-169.9%) | -$6.74 M(-121.7%) |
| Sept 2013 | - | -$3.67 M(+31.4%) | $31.05 M(-6.5%) |
| June 2013 | - | -$2.79 M(-1.6%) | $33.21 M(-3.3%) |
| Mar 2013 | - | -$2.84 M(-107.0%) | $34.33 M(+4.3%) |
| Dec 2012 | $32.91 M(-520.2%) | $40.36 M(-2766.7%) | $32.91 M(-516.8%) |
| Sept 2012 | - | -$1.51 M(-9.6%) | -$7.90 M(+22.6%) |
| June 2012 | - | -$1.67 M(-60.7%) | -$6.44 M(-28.0%) |
| Mar 2012 | - | -$4.26 M(+854.9%) | -$8.95 M(+14.2%) |
| Dec 2011 | -$7.83 M(-30.4%) | -$446.30 K(+643.8%) | -$7.83 M(-29.9%) |
| Sept 2011 | - | -$60.00 K(-98.6%) | -$11.17 M(-16.7%) |
| June 2011 | - | -$4.18 M(+32.7%) | -$13.40 M(+46.0%) |
| Mar 2011 | - | -$3.15 M(-16.8%) | -$9.18 M(-18.4%) |
| Dec 2010 | -$11.25 M(+112.8%) | -$3.78 M(+65.0%) | -$11.25 M(+21.2%) |
| Sept 2010 | - | -$2.29 M(-5273.1%) | -$9.28 M(+16.9%) |
| June 2010 | - | $44.30 K(-100.8%) | -$7.93 M(-17.5%) |
| Mar 2010 | - | -$5.22 M(+188.4%) | -$9.62 M(+82.0%) |
| Dec 2009 | -$5.28 M(-37.7%) | -$1.81 M(+91.0%) | -$5.28 M(+2.6%) |
| Sept 2009 | - | -$947.70 K(-42.2%) | -$5.15 M(-32.1%) |
| June 2009 | - | -$1.64 M(+84.9%) | -$7.59 M(-13.3%) |
| Mar 2009 | - | -$887.00 K(-47.1%) | -$8.75 M(+3.1%) |
| Dec 2008 | -$8.48 M(+155.9%) | -$1.68 M(-50.4%) | -$8.48 M(+24.6%) |
| Sept 2008 | - | -$3.38 M(+20.6%) | -$6.81 M(+98.7%) |
| June 2008 | - | -$2.81 M(+352.6%) | -$3.42 M(+452.6%) |
| Mar 2008 | - | -$619.80 K | -$619.80 K |
| Dec 2007 | -$3.32 M(+28.6%) | - | - |
| Dec 2006 | -$2.58 M(-82.3%) | - | - |
| Dec 2005 | -$14.57 M(+46.0%) | - | - |
| Dec 2004 | -$9.98 M(-63.0%) | - | - |
| Dec 2003 | -$26.96 M(+48.5%) | - | - |
| Dec 2002 | -$18.16 M(+81.5%) | - | - |
| Dec 2001 | -$10.00 M(+19.8%) | - | - |
| Dec 2000 | -$8.35 M(+19.5%) | - | - |
| Dec 1999 | -$6.99 M(-9.3%) | - | - |
| Dec 1998 | -$7.71 M | - | - |
FAQ
- What is Arbutus Biopharma annual cash flow from operations?
- What is the all time high annual CFO for Arbutus Biopharma?
- What is Arbutus Biopharma annual CFO year-on-year change?
- What is Arbutus Biopharma quarterly cash flow from operations?
- What is the all time high quarterly CFO for Arbutus Biopharma?
- What is Arbutus Biopharma quarterly CFO year-on-year change?
- What is Arbutus Biopharma TTM cash flow from operations?
- What is the all time high TTM CFO for Arbutus Biopharma?
- What is Arbutus Biopharma TTM CFO year-on-year change?
What is Arbutus Biopharma annual cash flow from operations?
The current annual CFO of ABUS is -$85.94 M
What is the all time high annual CFO for Arbutus Biopharma?
Arbutus Biopharma all-time high annual cash flow from operations is $32.91 M
What is Arbutus Biopharma annual CFO year-on-year change?
Over the past year, ABUS annual cash flow from operations has changed by -$50.58 M (-143.06%)
What is Arbutus Biopharma quarterly cash flow from operations?
The current quarterly CFO of ABUS is -$20.74 M
What is the all time high quarterly CFO for Arbutus Biopharma?
Arbutus Biopharma all-time high quarterly cash flow from operations is $40.36 M
What is Arbutus Biopharma quarterly CFO year-on-year change?
Over the past year, ABUS quarterly cash flow from operations has changed by -$1.44 M (-7.47%)
What is Arbutus Biopharma TTM cash flow from operations?
The current TTM CFO of ABUS is -$71.83 M
What is the all time high TTM CFO for Arbutus Biopharma?
Arbutus Biopharma all-time high TTM cash flow from operations is $34.33 M
What is Arbutus Biopharma TTM CFO year-on-year change?
Over the past year, ABUS TTM cash flow from operations has changed by +$6.10 M (+7.83%)